With its $2.9 billion acquisition of American Medical Systems Holdings Inc., Endo International PLC is further diversifying its specialty pharma portfolio into devices and services. The two companies announced an agreement April 11 in which Endo will acquire the urology device specialist for $30 per share, a move that furthers Endo's strategy to become a leader in the area of pelvic health services and products. [See Deal] The healthy offer represents a 34% premium over AMS' April 8 closing price – and is three times the device maker's 2010 sales of $538 million. The combined company is estimated to have sales of $2.68 billion.
Endo – once inordinately dependent on Lidoderm (lidocaine 5% patch) for revenues – has been in the midst of a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?